BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 21319871)

  • 1. Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus.
    Chwieduk CM
    Drugs; 2011 Feb; 71(3):349-61. PubMed ID: 21319871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sitagliptin: a review of its use in the management of type 2 diabetes mellitus.
    Dhillon S
    Drugs; 2010 Mar; 70(4):489-512. PubMed ID: 20205490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes.
    Giampietro O; Giampietro C; Bartola LD; Masoni MC; Matteucci E
    Drug Des Devel Ther; 2013; 7():99-104. PubMed ID: 23439744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.
    Scheen AJ; Charpentier G; Ostgren CJ; Hellqvist A; Gause-Nilsson I
    Diabetes Metab Res Rev; 2010 Oct; 26(7):540-9. PubMed ID: 20824678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial.
    Arechavaleta R; Seck T; Chen Y; Krobot KJ; O'Neill EA; Duran L; Kaufman KD; Williams-Herman D; Goldstein BJ
    Diabetes Obes Metab; 2011 Feb; 13(2):160-8. PubMed ID: 21199268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.
    Nauck MA; Meininger G; Sheng D; Terranella L; Stein PP;
    Diabetes Obes Metab; 2007 Mar; 9(2):194-205. PubMed ID: 17300595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study.
    Williams-Herman D; Johnson J; Teng R; Luo E; Davies MJ; Kaufman KD; Goldstein BJ; Amatruda JM
    Curr Med Res Opin; 2009 Mar; 25(3):569-83. PubMed ID: 19232032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sitagliptin.
    Violante R; Oliveira JH; Yoon KH; Reed VA; Yu MB; Bachmann OP; Lüdemann J; Chan JY
    Diabet Med; 2012 Nov; 29(11):e417-24. PubMed ID: 22375612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sitagliptin: new drug. Type 2 diabetes: limited efficacy, too many unknown risks.
    Prescrire Int; 2008 Feb; 17(93):12-5. PubMed ID: 18354861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
    Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
    Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sitagliptin.
    Lyseng-Williamson KA
    Drugs; 2007; 67(4):587-97. PubMed ID: 17352516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.
    Plosker GL
    Drugs; 2014 Feb; 74(2):223-42. PubMed ID: 24407560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes.
    Williams-Herman D; Johnson J; Teng R; Golm G; Kaufman KD; Goldstein BJ; Amatruda JM
    Diabetes Obes Metab; 2010 May; 12(5):442-51. PubMed ID: 20415693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.
    Bailey CJ; Green BD; Flatt PR
    Expert Opin Investig Drugs; 2010 Aug; 19(8):1017-25. PubMed ID: 20629618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes.
    Fonseca V; Staels B; Morgan JD; Shentu Y; Golm GT; Johnson-Levonas AO; Kaufman KD; Goldstein BJ; Steinberg H
    J Diabetes Complications; 2013; 27(2):177-83. PubMed ID: 23116881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Janumet: a combination product suitable for use in patients with Type 2 diabetes.
    Reynolds JK; Neumiller JJ; Campbell RK
    Expert Opin Investig Drugs; 2008 Oct; 17(10):1559-65. PubMed ID: 18808315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.
    Prescrire Int; 2009 Jun; 18(101):115. PubMed ID: 19637427
    [No Abstract]   [Full Text] [Related]  

  • 20. Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study.
    Migoya EM; Miller JL; Gutierrez M; Zheng W; Johnson-Levonas AO; Liu Q; Matthews CZ; Wagner JA; Gottesdiener KM
    Clin Drug Investig; 2010; 30(12):855-66. PubMed ID: 20923244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.